Nuvectis Pharma Inc. (NVCT) News
Filter NVCT News Items
NVCT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVCT News Highlights
- NVCT's 30 day story count now stands at 2.
- Over the past 23 days, the trend for NVCT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, DRUG and LEE are the most mentioned tickers in articles about NVCT.
Latest NVCT News From Around the Web
Below are the latest news stories about NUVECTIS PHARMA INC that investors may wish to consider to help them evaluate NVCT as an investment opportunity.
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in CholangiocarcinomaMitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by investigators from Mayo Clinic in PDX models of cholangiocarcinoma (presented at the 2023 American Association for Cancer Research ("AACR"))NXP800 was granted orphan drug designation by the FDA for the treatment of cholangiocarcinoma in August 2023 Fort Lee, NJ, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pha |
Nuvectis Pharma Insiders Added US$3.75m Of Stock To Their HoldingsQuite a few insiders have dramatically grown their holdings in Nuvectis Pharma, Inc. ( NASDAQ:NVCT ) over the past 12... |
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business HighlightsPhase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid TumorsNXP800 Granted Orphan Drug Designation for the Treatment of CholangiocarcinomaNXP800 Phase 1a and Preclinical Data Presentations for NXP800 and NXP900 at Key Medical Conferences FORT LEE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a cli |
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial CancerFort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced an upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (November 16-18, 2023, Boston, MA). Abstract Titles and PresentersPresentation Detai |
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate PresentationFort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows: Date Tuesday, September |
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP800 at the 2023 AACR Special Conference In Cancer Research: Ovarian Cancer (October 5-7, 2023, Boston, MA) and for NXP800 and NXP900 at the 2023 AA |
With 67% ownership, insiders at Nuvectis Pharma, Inc. (NASDAQ:NVCT) are pretty optimistic and have been buying recentlyKey Insights Significant insider control over Nuvectis Pharma implies vested interests in company growth The top 4... |
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical TrialFort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family (“SFK”). The study is designed to evaluate the safety, tolerability |